IsomAb, a biopharmaceutical company born from the University of Nottingham, has secured £7.5 million in funding to propel its innovative treatment for peripheral arterial disease (PAD) in diabetic patients towards clinical trials.
This significant investment round, led by Broadview Ventures and backed by a consortium of renowned organisations (such as MEIF Proof of Concept & Early Stage Fund, Mercia’s EIS funds and existing investor SCVC), fuels hope for millions struggling with the debilitating consequences of PAD, particularly those facing the life-altering threat of amputation.
Earlier this month, Una Health secured $2.5M to expand its battle against diabetes as well, while late last year, Twin Health cemented $50M to tackle lifestyle diseases like diabetes.
PAD: A crippling challenge for diabetics
PAD, characterised by the buildup of fatty deposits that obstruct arteries in the legs and feet, significantly impacts individuals with diabetes. While the body typically compensates for restricted blood flow by generating new blood vessels (angiogenesis), this process falters in diabetics, leading to a cascade of complications. Ulcers, infections, and tissue damage can ultimately necessitate amputation, a life-altering and emotionally taxing procedure.
IsomAb’s antibody-wielding approach
Professors David Bates and Steve Harper, the visionary founders of IsomAb, identified a culprit behind this impaired angiogenesis: a protein called VEGF-A165b. Their groundbreaking therapy leverages a specifically designed antibody to neutralise this protein’s effects, paving the way for the growth of new blood vessels and potentially preventing the devastating need for amputation.
Funding fuels the future
The recent funding round, a testament to the promise of IsomAb’s approach, brings together a diverse group of investors. Broadview Ventures, dedicated to accelerating advancements in cardiovascular health, leads the charge. They are joined by the MEIF Proof of Concept & Early Stage Fund, Mercia’s EIS funds, SCVC, and existing investor SCVC, demonstrating a collective belief in IsomAb’s potential to enhance PAD treatment.
“This funding is a crucial springboard for us to advance our program towards clinical trials,” expressed Jackie Turnbull, CEO of IsomAb, with evident enthusiasm. “We are incredibly grateful for the support of these esteemed investors, who share our vision of alleviating the suffering of millions living with PAD and diabetes.”
Beyond hype: The potential impact
While avoiding overly promotional language, it’s crucial to acknowledge the significant implications of IsomAb’s progress. Benjamin Kreitman, Principal at Broadview Ventures, highlights the unmet medical need: “Peripheral artery disease remains a significant challenge, and IsomAb’s targeted approach has the potential to improve clinical care for millions of patients.”
Hannah Tapsell Chapman, of Mercia Ventures, underscores the broader applicability: “IsomAb’s approach offers a fresh perspective, not just for treating diabetics but potentially for addressing PAD in a wider context.” This hints at the therapy’s potential to extend its reach beyond its initial focus.
Investing in innovation, investing in hope
The MEIF’s involvement in this endeavour signifies its commitment to fostering regional innovation with global impact. Keira Shepperson, Investment Director at the British Business Bank, emphasises this mission: “The MEIF is proud to support IsomAb, a shining example of regional innovation tackling a global health challenge.”
The road ahead
With this vital funding and a dedicated team, IsomAb is poised to embark on the next crucial phase of development. As they progress towards clinical trials, the hope for millions struggling with PAD grows brighter. The potential to prevent amputations and offer a non-invasive treatment option holds immense promise, not just for individual patients but for healthcare systems worldwide.
